Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer (IES)

21. April 2014 aktualisiert von: Pfizer

Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen

To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

4740

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Argentinien
      • Buenos Aires, Argentinien, 1181
        • Pfizer Investigational Site
      • Cordoba, Argentinien, X5000AA1
        • Pfizer Investigational Site
    • Buenos Aires
      • Haedo, Buenos Aires, Argentinien, 1706
        • Pfizer Investigational Site
      • San Isidro, Buenos Aires, Argentinien, 1642
        • Pfizer Investigational Site
      • San Martin, Buenos Aires, Argentinien, 1650
        • Pfizer Investigational Site
    • Capital Federal
      • Buenos Aires, Capital Federal, Argentinien, 1406
        • Pfizer Investigational Site
      • Buenos Aires, Capital Federal, Argentinien
        • Pfizer Investigational Site
      • Buenos Aires, Capital Federal, Argentinien, 1426
        • Pfizer Investigational Site
      • Buenos Aires, Capital Federal, Argentinien, 1417
        • Pfizer Investigational Site
      • Buenos Aires, Capital Federal, Argentinien, 1425
        • Pfizer Investigational Site
    • Pcia. de Santa Fe
      • Rosario 2000, Pcia. de Santa Fe, Argentinien
        • Pfizer Investigational Site
    • Santa Fe
      • Rosario, Santa Fe, Argentinien, 2000
        • Pfizer Investigational Site
  • Australien
    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
        • Pfizer Investigational Site
      • Dubbo, New South Wales, Australien, 2830
        • Pfizer Investigational Site
      • Liverpool, New South Wales, Australien, 2170
        • Pfizer Investigational Site
      • Waratah, New South Wales, Australien, 2298
        • Pfizer Investigational Site
    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • Pfizer Investigational Site
    • Victoria
      • Bendigo, Victoria, Australien, 3552
        • Pfizer Investigational Site
      • Box Hill, Victoria, Australien, 3128
        • Pfizer Investigational Site
      • Ringwood East, Victoria, Australien, 3135
        • Pfizer Investigational Site
  • Belgien
      • Antwerpen, Belgien, 2020
        • Pfizer Investigational Site
      • Arlon, Belgien, 6700
        • Pfizer Investigational Site
      • Baudour, Belgien, 7331
        • Pfizer Investigational Site
      • Brasschaat, Belgien, 2930
        • Pfizer Investigational Site
      • Bruxelles, Belgien, 1000
        • Pfizer Investigational Site
      • Bruxelles, Belgien, 1180
        • Pfizer Investigational Site
      • Charleroi, Belgien, 6000
        • Pfizer Investigational Site
      • Edegem, Belgien, 2650
        • Pfizer Investigational Site
      • Genk, Belgien, 3600
        • Pfizer Investigational Site
      • Haine St. Paul, Belgien, 7100
        • Pfizer Investigational Site
      • Hasselt, Belgien, 3500
        • Pfizer Investigational Site
      • Kraainem, Belgien, 1950
        • Pfizer Investigational Site
      • La Louviere, Belgien, 7100
        • Pfizer Investigational Site
      • Leuven, Belgien, 3000
        • Pfizer Investigational Site
      • Liege, Belgien, 4000
        • Pfizer Investigational Site
      • Merksem, Belgien, 2170
        • Pfizer Investigational Site
      • Namur, Belgien, 5000
        • Pfizer Investigational Site
      • Verviers, Belgien, 4800
        • Pfizer Investigational Site
      • Wilrijk, Belgien, 2610
        • Pfizer Investigational Site
  • Bosnien und Herzegowina
      • Sarajevo, Bosnien und Herzegowina, 71000
        • Pfizer Investigational Site
  • Bulgarien
      • Plovdiv, Bulgarien, 4004
        • Pfizer Investigational Site
      • Sofia, Bulgarien, 1756
        • Pfizer Investigational Site
      • Sofia, Bulgarien, 1504
        • Pfizer Investigational Site
      • Sofia, Bulgarien, 1784
        • Pfizer Investigational Site
      • Stara Zagora, Bulgarien, 6003
        • Pfizer Investigational Site
  • Deutschland
      • Berlin, Deutschland, 10117
        • Pfizer Investigational Site
      • Berlin, Deutschland, 13353
        • Pfizer Investigational Site
      • Chemnitz, Deutschland, 09126
        • Pfizer Investigational Site
      • Erlangen, Deutschland, 91054
        • Pfizer Investigational Site
      • Freiburg, Deutschland, 79106
        • Pfizer Investigational Site
      • Gera, Deutschland, 07548
        • Pfizer Investigational Site
      • Greiz, Deutschland, 07973
        • Pfizer Investigational Site
      • Halle, Deutschland, 06120
        • Pfizer Investigational Site
      • Halle, Deutschland, 06110
        • Pfizer Investigational Site
      • Hamburg, Deutschland, 22081
        • Pfizer Investigational Site
      • Hildburghausen, Deutschland, 98646
        • Pfizer Investigational Site
      • Leipzig, Deutschland, 04129
        • Pfizer Investigational Site
      • Luebeck, Deutschland, 23538
        • Pfizer Investigational Site
      • Muenchen, Deutschland, 80335
        • Pfizer Investigational Site
      • Riesa, Deutschland, 01589
        • Pfizer Investigational Site
      • Rodewisch, Deutschland, 08228
        • Pfizer Investigational Site
      • Saarbruecken, Deutschland, 66113
        • Pfizer Investigational Site
      • Suhl, Deutschland, 98527
        • Pfizer Investigational Site
      • Weiden, Deutschland, 92637
        • Pfizer Investigational Site
  • Dänemark
      • Aarhus C, Dänemark, 8000
        • Pfizer Investigational Site
      • Esbjerg, Dänemark, 6700
        • Pfizer Investigational Site
      • Herlev, Dänemark, 2730
        • Pfizer Investigational Site
      • Herning, Dänemark, 7400
        • Pfizer Investigational Site
      • Hilleroed, Dänemark, 3400
        • Pfizer Investigational Site
      • Koebenhavn OE, Dänemark, 2100
        • Pfizer Investigational Site
      • Naestved, Dänemark, 4700
        • Pfizer Investigational Site
      • Roskilde, Dänemark, 4000
        • Pfizer Investigational Site
      • Vejle, Dänemark, 7100
        • Pfizer Investigational Site
      • Viborg, Dänemark, 8800
        • Pfizer Investigational Site
  • Estland
      • Tartu, Estland, 51014
        • Pfizer Investigational Site
  • Frankreich
      • Angers, Frankreich, 49033 Cedex 01
        • Pfizer Investigational Site
      • Annecy Cedex, Frankreich, 74011
        • Pfizer Investigational Site
      • Avignon Cedex 2, Frankreich, 84082
        • Pfizer Investigational Site
      • Bordeaux, Frankreich, 33030 Cedex
        • Pfizer Investigational Site
      • Bordeaux, Frankreich, 33300 Cedex
        • Pfizer Investigational Site
      • Brest, Frankreich, 29609 Cedex
        • Pfizer Investigational Site
      • Caen, Frankreich, 14052 Cedex
        • Pfizer Investigational Site
      • Caen Cedex 05, Frankreich, 14076
        • Pfizer Investigational Site
      • Clermont Ferrand, Frankreich, 63011
        • Pfizer Investigational Site
      • Evreux, Frankreich, 27000
        • Pfizer Investigational Site
      • Lagny Sur Marne, Frankreich, 77405 Cedex
        • Pfizer Investigational Site
      • Le Havre, Frankreich, 76600
        • Pfizer Investigational Site
      • Le Mans, Frankreich, 72000
        • Pfizer Investigational Site
      • Lille, Frankreich, 59020 Cedex
        • Pfizer Investigational Site
      • Lyon, Frankreich, 69373
        • Pfizer Investigational Site
      • Marseille, Frankreich, 13273
        • Pfizer Investigational Site
      • Meaux, Frankreich, 77100
        • Pfizer Investigational Site
      • Montbeliard, Frankreich, 25209 Cedex
        • Pfizer Investigational Site
      • Mulhouse, Frankreich, 68070 Cedex
        • Pfizer Investigational Site
      • Nice, Frankreich, 06189
        • Pfizer Investigational Site
      • Paris, Frankreich, 75248 Cedex 5
        • Pfizer Investigational Site
      • Paris, Frankreich, 75970 Cedex 20
        • Pfizer Investigational Site
      • Perpignan, Frankreich, 66046
        • Pfizer Investigational Site
      • Rennes, Frankreich, 35042
        • Pfizer Investigational Site
      • Rouen, Frankreich, 76038 Cedex
        • Pfizer Investigational Site
      • Saint-Herblain, Frankreich, 44805
        • Pfizer Investigational Site
      • St Cloud, Frankreich, 92210
        • Pfizer Investigational Site
      • Strasbourg, Frankreich, 67091 Cedex
        • Pfizer Investigational Site
      • Toulouse, Frankreich, 31502
        • Pfizer Investigational Site
  • Griechenland
    • Attiki
      • Athens, Attiki, Griechenland, 115 22
        • Pfizer Investigational Site
      • Athens, Attiki, Griechenland, 115 28
        • Pfizer Investigational Site
    • Crete
      • Heraklion, Crete, Griechenland, 71 110
        • Pfizer Investigational Site
  • Hongkong
      • New Territories, Hongkong
        • Pfizer Investigational Site
  • Irland
      • Cork, Irland
        • Pfizer Investigational Site
      • Cork, Ireland, Irland
        • Pfizer Investigational Site
      • Dublin, Irland
        • Pfizer Investigational Site
      • Dublin 9, Irland
        • Pfizer Investigational Site
      • Galway, Irland
        • Pfizer Investigational Site
  • Israel
      • Haifa, Israel
        • Pfizer Investigational Site
      • Haifa, Israel, 34362
        • Pfizer Investigational Site
      • Jerusalem, Israel, 91120
        • Pfizer Investigational Site
      • Jerusalem, Israel
        • Pfizer Investigational Site
      • Kfar Saba, Israel
        • Pfizer Investigational Site
      • Petah Tikva, Israel
        • Pfizer Investigational Site
      • Rehovot, Israel
        • Pfizer Investigational Site
  • Italien
      • Alba (CN), Italien, 12051
        • Pfizer Investigational Site
      • Aviano (PN), Italien, 33081
        • Pfizer Investigational Site
      • Bergamo, Italien, 24128
        • Pfizer Investigational Site
      • Biella, Italien, 13900
        • Pfizer Investigational Site
      • Cagliari, Italien, 09121
        • Pfizer Investigational Site
      • Casale Monferrato, AL, Italien, 15033
        • Pfizer Investigational Site
      • Correggio, Italien, 42015
        • Pfizer Investigational Site
      • Cremona, Italien, 26100
        • Pfizer Investigational Site
      • Cuneo, Italien, 12100
        • Pfizer Investigational Site
      • Fermo FM, Italien, 63023
        • Pfizer Investigational Site
      • Firenze, Italien, 50134
        • Pfizer Investigational Site
      • Genova, Italien, 16132
        • Pfizer Investigational Site
      • Genova, Italien, 16128
        • Pfizer Investigational Site
      • Lecco, Italien, 23900
        • Pfizer Investigational Site
      • Lodi, Italien, 20075
        • Pfizer Investigational Site
      • Mantova, Italien, 46100
        • Pfizer Investigational Site
      • Milano, Italien, 20133
        • Pfizer Investigational Site
      • Milano, Italien, 20121
        • Pfizer Investigational Site
      • Milano, Italien, 20141
        • Pfizer Investigational Site
      • Milano, Italien, 21053
        • Pfizer Investigational Site
      • Modena, Italien, 41100
        • Pfizer Investigational Site
      • Monserrato (CA), Italien, 09042
        • Pfizer Investigational Site
      • Monza, Italien, 20052
        • Pfizer Investigational Site
      • Napoli, Italien, 80131
        • Pfizer Investigational Site
      • Palermo, Italien, 90139
        • Pfizer Investigational Site
      • Parma, Italien, 43100
        • Pfizer Investigational Site
      • Perugia, Italien, 06132
        • Pfizer Investigational Site
      • Piacenza, Italien, 29100
        • Pfizer Investigational Site
      • Pietra Ligure (SV), Italien, 17027
        • Pfizer Investigational Site
      • Pisa, Italien, 56100
        • Pfizer Investigational Site
      • Reggio Emilia, Italien, 42100
        • Pfizer Investigational Site
      • Roma, Italien, 00148
        • Pfizer Investigational Site
      • Sassari, Italien, 07100
        • Pfizer Investigational Site
      • Terni, Italien, 05100
        • Pfizer Investigational Site
      • Thiene (VI), Italien, 36016
        • Pfizer Investigational Site
      • Torino, Italien, 10126
        • Pfizer Investigational Site
      • Tortona, Italien, 15057
        • Pfizer Investigational Site
      • Trescore Balneario BG, Italien, 24069
        • Pfizer Investigational Site
      • Treviglio (BG), Italien, 24047
        • Pfizer Investigational Site
      • Varese, Italien, 21100
        • Pfizer Investigational Site
    • Modena
      • Carpi, Modena, Italien, 41012
        • Pfizer Investigational Site
  • Kroatien
      • Osijek, Kroatien
        • Pfizer Investigational Site
      • Split, Kroatien
        • Pfizer Investigational Site
      • Zagreb, Kroatien, 10000
        • Pfizer Investigational Site
      • Zagreb, Kroatien
        • Pfizer Investigational Site
  • Luxemburg
      • Luxembourg, Luxemburg, 1210
        • Pfizer Investigational Site
  • Malta
      • Floriana, Malta, VLT 14
        • Pfizer Investigational Site
  • Neuseeland
      • Auckland, Neuseeland, 1142
        • Pfizer Investigational Site
    • Waikato
      • Hamilton, Waikato, Neuseeland, 2021
        • Pfizer Investigational Site
  • Niederlande
      • Amersfoort, Niederlande, 3818 ES
        • Pfizer Investigational Site
      • Amsterdam, Niederlande, 1105 AZ
        • Pfizer Investigational Site
      • Amsterdam, Niederlande, 1066 CX
        • Pfizer Investigational Site
      • Amsterdam, Niederlande, 1061 AE
        • Pfizer Investigational Site
      • Apeldoorn, Niederlande, 7300 DS
        • Pfizer Investigational Site
      • Blaricum, Niederlande, 1261 AN
        • Pfizer Investigational Site
      • Breda, Niederlande, 4818 CK
        • Pfizer Investigational Site
      • Delft, Niederlande, 2625 AD
        • Pfizer Investigational Site
      • Den Haag, Niederlande, 2545 CH
        • Pfizer Investigational Site
      • Eindhoven, Niederlande, 5623 EJ
        • Pfizer Investigational Site
      • Enschede, Niederlande, 7513 ER
        • Pfizer Investigational Site
      • Groningen, Niederlande, 9728 NZ
        • Pfizer Investigational Site
      • Groningen, Niederlande, 9700 RM
        • Pfizer Investigational Site
      • Hengelo, Niederlande, 7555 DL
        • Pfizer Investigational Site
      • Leeuwarden, Niederlande, 8934 AD
        • Pfizer Investigational Site
      • Leiden, Niederlande, 2333 ZA
        • Pfizer Investigational Site
      • Leidschendam, Niederlande, 2262 BA
        • Pfizer Investigational Site
      • Podybus 90153, Niederlande, 5200 ME Den Bosch
        • Pfizer Investigational Site
      • Roermond, Niederlande, 6043 CV
        • Pfizer Investigational Site
      • Sittard, Niederlande, 6131 BK
        • Pfizer Investigational Site
      • Utrecht, Niederlande, 3582 KE
        • Pfizer Investigational Site
      • Veldhoven, Niederlande, 5504 DB
        • Pfizer Investigational Site
      • Zaandam, Niederlande, 1502 DV
        • Pfizer Investigational Site
  • Norwegen
      • Bergen, Norwegen, 5021
        • Pfizer Investigational Site
      • Bodo, Norwegen, 8092
        • Pfizer Investigational Site
      • Fredrikstad, Norwegen, 1603
        • Pfizer Investigational Site
      • Haugesund, Norwegen, 5390
        • Pfizer Investigational Site
      • Levanger, Norwegen, 7600
        • Pfizer Investigational Site
      • Mo i Rana, Norwegen, 8607
        • Pfizer Investigational Site
      • Molde, Norwegen, 6407
        • Pfizer Investigational Site
      • Notodden, Norwegen, 3674
        • Pfizer Investigational Site
      • Oslo, Norwegen
        • Pfizer Investigational Site
      • Rissa, Norwegen, 7100
        • Pfizer Investigational Site
      • Rjukan, Norwegen, 3660
        • Pfizer Investigational Site
      • Sandefjord, Norwegen
        • Pfizer Investigational Site
      • Tonsberg, Norwegen, 3103
        • Pfizer Investigational Site
      • Tromso, Norwegen, 9038
        • Pfizer Investigational Site
      • Tromsø, Norwegen, 9038
        • Pfizer Investigational Site
  • Peru
      • Lima, Peru, L34
        • Pfizer Investigational Site
  • Polen
      • Gdansk, Polen, 80-952
        • Pfizer Investigational Site
      • Gliwice, Polen, 44-101
        • Pfizer Investigational Site
      • Krakow, Polen, 31-115
        • Pfizer Investigational Site
      • Krakow, Polen, 31-826
        • Pfizer Investigational Site
      • Lodz, Polen, 93-509
        • Pfizer Investigational Site
      • Opole, Polen, 45-060
        • Pfizer Investigational Site
      • Poznan, Polen, 61-878
        • Pfizer Investigational Site
      • Sopot, Polen, 81-756
        • Pfizer Investigational Site
      • Warszawa, Polen, 02-781
        • Pfizer Investigational Site
  • Portugal
      • Coimbra, Portugal, 3040
        • Pfizer Investigational Site
      • Coimbra, Portugal
        • Pfizer Investigational Site
      • Evora, Portugal, 7000-811
        • Pfizer Investigational Site
  • Rumänien
      • Bucuresti, Rumänien, 72435
        • Pfizer Investigational Site
      • Cluj Napoca, Rumänien, 400015
        • Pfizer Investigational Site
      • Timisoara, Rumänien, 300223
        • Pfizer Investigational Site
  • Russische Föderation
      • St. Petersburg, Russische Föderation, 197758
        • Pfizer Investigational Site
  • Schweden
      • Boras, Schweden, 501 82
        • Pfizer Investigational Site
      • Borås, Schweden, 50182
        • Pfizer Investigational Site
      • Goteborg, Schweden, 413 45
        • Pfizer Investigational Site
      • Halmstad, Schweden, 301 85
        • Pfizer Investigational Site
      • Helsingborg, Schweden, 251 87
        • Pfizer Investigational Site
      • Kristianstad, Schweden, 291 85
        • Pfizer Investigational Site
      • Linkoping, Schweden, 581 85
        • Pfizer Investigational Site
      • Lund, Schweden, 221 85
        • Pfizer Investigational Site
      • Malmo, Schweden, 205 02
        • Pfizer Investigational Site
      • Motala, Schweden, 591 85
        • Pfizer Investigational Site
      • Norrkoping, Schweden, 601 82
        • Pfizer Investigational Site
      • Nässjö, Schweden, 575 81
        • Pfizer Investigational Site
      • Varnamo, Schweden, 331 85
        • Pfizer Investigational Site
      • Vasteras, Schweden, 721 89
        • Pfizer Investigational Site
      • Vastervik, Schweden, 59381
        • Pfizer Investigational Site
      • Vaxjo, Schweden, 351 85
        • Pfizer Investigational Site
  • Schweiz
      • Basel, Schweiz, CH-4031
        • Pfizer Investigational Site
      • Bellinzona, Schweiz, CH-6500
        • Pfizer Investigational Site
      • Bern, Schweiz, 3010
        • Pfizer Investigational Site
      • Bern, Schweiz, CH-3012
        • Pfizer Investigational Site
      • Genève, Schweiz, CH-1211
        • Pfizer Investigational Site
  • Serbien
      • Belgrade, Serbien, 11000
        • Pfizer Investigational Site
      • Sremska Kamenica, Serbien, 21204
        • Pfizer Investigational Site
  • Slowakei
      • Banska Bystrica, Slowakei, 97517
        • Pfizer Investigational Site
      • Bratislava, Slowakei, SK-83310
        • Pfizer Investigational Site
      • Kosice, Slowakei, 041 90
        • Pfizer Investigational Site
  • Slowenien
      • Ljubljana, Slowenien, 1000
        • Pfizer Investigational Site
  • Spanien
      • Albacete, Spanien, 02006
        • Pfizer Investigational Site
      • Alicante, Spanien, 03010
        • Pfizer Investigational Site
      • Badajoz, Spanien, 06008
        • Pfizer Investigational Site
      • Badajoz, Spanien, 06080
        • Pfizer Investigational Site
      • Cordoba, Spanien, 14004
        • Pfizer Investigational Site
      • Guadalajara, Spanien, 19002
        • Pfizer Investigational Site
      • Lleida, Spanien, 25198
        • Pfizer Investigational Site
      • Madrid, Spanien, 28034
        • Pfizer Investigational Site
      • Madrid, Spanien, 28041
        • Pfizer Investigational Site
      • Madrid, Spanien, 28040
        • Pfizer Investigational Site
      • Valencia, Spanien, 46014
        • Pfizer Investigational Site
      • Zaragoza, Spanien, 50009
        • Pfizer Investigational Site
    • Alicante
      • Alcoy, Alicante, Spanien, 03804
        • Pfizer Investigational Site
      • Elche, Alicante, Spanien, 03203
        • Pfizer Investigational Site
      • San Juan de Alicante, Alicante, Spanien, 03550
        • Pfizer Investigational Site
      • Sant Joan D'Alacant, Alicante, Spanien, 03550
        • Pfizer Investigational Site
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • Pfizer Investigational Site
      • Badalona, Barcelona, Spanien, 08911
        • Pfizer Investigational Site
      • Terrassa, Barcelona, Spanien, 08227
        • Pfizer Investigational Site
      • Terrassa, Barcelona, Spanien, 08221
        • Pfizer Investigational Site
    • Guipuzcoa
      • San Sebastian, Guipuzcoa, Spanien, 20014
        • Pfizer Investigational Site
    • Huesca
      • Barbastro, Huesca, Spanien, 22300
        • Pfizer Investigational Site
    • Tarragona
      • Reus, Tarragona, Spanien, 43201
        • Pfizer Investigational Site
  • Südafrika
      • Observatory, Südafrika, 7925
        • Pfizer Investigational Site
    • Gauteng
      • Johannesburg, Gauteng, Südafrika, 2196
        • Pfizer Investigational Site
  • Tschechische Republik
      • Brno, Tschechische Republik, 656 53
        • Pfizer Investigational Site
      • Ceske Budejovice, Tschechische Republik, 370 87
        • Pfizer Investigational Site
      • Prague 2, Tschechische Republik, 12808
        • Pfizer Investigational Site
  • Ungarn
      • Budapest, Ungarn, 1082
        • Pfizer Investigational Site
      • Budapest, Ungarn, 1122
        • Pfizer Investigational Site
      • Budapest, Ungarn, 1145
        • Pfizer Investigational Site
  • Vereinigte Staaten
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35205
        • Pfizer Investigational Site
      • Birmingham, Alabama, Vereinigte Staaten, 35213
        • Pfizer Investigational Site
      • Birmingham, Alabama, Vereinigte Staaten, 35235
        • Pfizer Investigational Site
    • Arizona
      • Green Valley, Arizona, Vereinigte Staaten, 85614
        • Pfizer Investigational Site
      • Green Velley, Arizona, Vereinigte Staaten, 85614
        • Pfizer Investigational Site
      • Tucson, Arizona, Vereinigte Staaten, 85715
        • Pfizer Investigational Site
      • Tucson, Arizona, Vereinigte Staaten, 85712
        • Pfizer Investigational Site
      • Tucson, Arizona, Vereinigte Staaten, 85710
        • Pfizer Investigational Site
      • Tucson, Arizona, Vereinigte Staaten, 85704
        • Pfizer Investigational Site
      • Tucson, Arizona, Vereinigte Staaten, 85745
        • Pfizer Investigational Site
    • Colorado
      • Boulder, Colorado, Vereinigte Staaten, 80304
        • Pfizer Investigational Site
      • Colorado Springs, Colorado, Vereinigte Staaten, 80909
        • Pfizer Investigational Site
      • Denver, Colorado, Vereinigte Staaten, 80218
        • Pfizer Investigational Site
      • Fort Collins, Colorado, Vereinigte Staaten, 80528
        • Pfizer Investigational Site
      • Lakewood, Colorado, Vereinigte Staaten, 80228
        • Pfizer Investigational Site
      • Thornton, Colorado, Vereinigte Staaten, 80260
        • Pfizer Investigational Site
    • Florida
      • Jacksonville, Florida, Vereinigte Staaten, 32207
        • Pfizer Investigational Site
      • Jacksonville, Florida, Vereinigte Staaten, 32204
        • Pfizer Investigational Site
      • Jacksonville Beach, Florida, Vereinigte Staaten, 32250
        • Pfizer Investigational Site
      • Ocala, Florida, Vereinigte Staaten, 34474
        • Pfizer Investigational Site
      • Orange Park, Florida, Vereinigte Staaten, 32073
        • Pfizer Investigational Site
    • Indiana
      • Fishers, Indiana, Vereinigte Staaten, 46038
        • Pfizer Investigational Site
      • Fishers, Indiana, Vereinigte Staaten, 46037
        • Pfizer Investigational Site
      • Indianapolis, Indiana, Vereinigte Staaten, 46227
        • Pfizer Investigational Site
      • Indianapolis, Indiana, Vereinigte Staaten, 46219
        • Pfizer Investigational Site
      • Indianapolis, Indiana, Vereinigte Staaten, IN 46219
        • Pfizer Investigational Site
    • Iowa
      • Cedar Rapids, Iowa, Vereinigte Staaten, 52403
        • Pfizer Investigational Site
    • Massachusetts
      • Pittsfield, Massachusetts, Vereinigte Staaten, 01201
        • Pfizer Investigational Site
    • New York
      • Albany, New York, Vereinigte Staaten, 12206
        • Pfizer Investigational Site
      • Latham, New York, Vereinigte Staaten, 12110-0610
        • Pfizer Investigational Site
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97225
        • Pfizer Investigational Site
      • Portland, Oregon, Vereinigte Staaten, 97227
        • Pfizer Investigational Site
    • Texas
      • Arlington, Texas, Vereinigte Staaten, 76014-2084
        • Pfizer Investigational Site
      • Bedford, Texas, Vereinigte Staaten, 76022
        • Pfizer Investigational Site
      • Dallas, Texas, Vereinigte Staaten, 75231
        • Pfizer Investigational Site
      • Dallas, Texas, Vereinigte Staaten, 75230-2510
        • Pfizer Investigational Site
      • Dallas, Texas, Vereinigte Staaten, 75246
        • Pfizer Investigational Site
      • El Paso, Texas, Vereinigte Staaten, 79902
        • Pfizer Investigational Site
      • El Paso, Texas, Vereinigte Staaten, 79915
        • Pfizer Investigational Site
      • Garland, Texas, Vereinigte Staaten, 75042
        • Pfizer Investigational Site
      • Houston, Texas, Vereinigte Staaten, 77030
        • Pfizer Investigational Site
      • Houston, Texas, Vereinigte Staaten, 77024
        • Pfizer Investigational Site
      • Houston, Texas, Vereinigte Staaten, 77074
        • Pfizer Investigational Site
      • Houston, Texas, Vereinigte Staaten, 77029
        • Pfizer Investigational Site
      • Longview, Texas, Vereinigte Staaten, 75601
        • Pfizer Investigational Site
      • McAllen, Texas, Vereinigte Staaten, 78503
        • Pfizer Investigational Site
      • Mesquite, Texas, Vereinigte Staaten, 75150
        • Pfizer Investigational Site
      • Odessa, Texas, Vereinigte Staaten, 79761
        • Pfizer Investigational Site
      • Pasadena, Texas, Vereinigte Staaten, 77502
        • Pfizer Investigational Site
      • Plano, Texas, Vereinigte Staaten, 75075-7787
        • Pfizer Investigational Site
      • San Antonio, Texas, Vereinigte Staaten, 78217
        • Pfizer Investigational Site
      • Sherman, Texas, Vereinigte Staaten, 75090
        • Pfizer Investigational Site
      • Sugar Land, Texas, Vereinigte Staaten, 77479
        • Pfizer Investigational Site
      • Tyler, Texas, Vereinigte Staaten, 75702
        • Pfizer Investigational Site
      • Weslaco, Texas, Vereinigte Staaten, 78596
        • Pfizer Investigational Site
    • Washington
      • Spokane, Washington, Vereinigte Staaten, 99202
        • Pfizer Investigational Site
      • Spokane, Washington, Vereinigte Staaten, 99218
        • Pfizer Investigational Site
  • Vereinigtes Königreich
      • Belfast, Vereinigtes Königreich, BT97AB
        • Pfizer Investigational Site
      • Bradford, Vereinigtes Königreich, BD9 6RJ
        • Pfizer Investigational Site
      • Bristol, Vereinigtes Königreich, BS10 5NB
        • Pfizer Investigational Site
      • Cardiff, Vereinigtes Königreich, CF14 2TL
        • Pfizer Investigational Site
      • Coventry, Vereinigtes Königreich, CV2 2DX
        • Pfizer Investigational Site
      • East Kilbride, Vereinigtes Königreich, G75 8RG
        • Pfizer Investigational Site
      • Huddersfield, Vereinigtes Königreich, HD3 3EA
        • Pfizer Investigational Site
      • Leeds, Vereinigtes Königreich, LS9 7TF
        • Pfizer Investigational Site
      • Leeds, Vereinigtes Königreich, LS1 3EX
        • Pfizer Investigational Site
      • Lincoln, Vereinigtes Königreich
        • Pfizer Investigational Site
      • London, Vereinigtes Königreich, W6 8RF
        • Pfizer Investigational Site
      • London, Vereinigtes Königreich, NW3 2QG
        • Pfizer Investigational Site
      • London, Vereinigtes Königreich, N18 1QX
        • Pfizer Investigational Site
      • London, Vereinigtes Königreich, SW17 0QT
        • Pfizer Investigational Site
      • London, Vereinigtes Königreich, N19 5NF
        • Pfizer Investigational Site
      • Luton, Vereinigtes Königreich, LU4 0DZ
        • Pfizer Investigational Site
      • Manchester, Vereinigtes Königreich, M20 4BX
        • Pfizer Investigational Site
      • Sheffield, Vereinigtes Königreich, S10 2SJ
        • Pfizer Investigational Site
      • Shrewsbury, Vereinigtes Königreich
        • Pfizer Investigational Site
      • Somerset, Vereinigtes Königreich, BA21 4AT
        • Pfizer Investigational Site
      • Southampton, Vereinigtes Königreich, S016 6YD
        • Pfizer Investigational Site
      • Steeton, Vereinigtes Königreich, BD20 6TD
        • Pfizer Investigational Site
      • Stoke on Trent, Vereinigtes Königreich, ST4 6QG
        • Pfizer Investigational Site
      • Telford, Vereinigtes Königreich, TF1 6TF
        • Pfizer Investigational Site
      • Wythenshawe, Manchester, Vereinigtes Königreich, M23 9LT
        • Pfizer Investigational Site
    • Cambs
      • Huntingdon, Cambs, Vereinigtes Königreich, PE18 8NT
        • Pfizer Investigational Site
    • Dorset
      • Bournemouth, Dorset, Vereinigtes Königreich, BH7 7DW
        • Pfizer Investigational Site
    • East Yorkshire
      • Hull, East Yorkshire, Vereinigtes Königreich, HU16 5JQ
        • Pfizer Investigational Site
    • Essex
      • Epping, Essex, Vereinigtes Königreich, CM166TN
        • Pfizer Investigational Site
      • Westcliff-On-Sea, Essex, Vereinigtes Königreich, SS0 0RY
        • Pfizer Investigational Site
    • Gwent
      • Newport, Gwent, Vereinigtes Königreich, NP6 2UB
        • Pfizer Investigational Site
    • Gwynedd
      • Bangor, Gwynedd, Vereinigtes Königreich, LL57 2PW
        • Pfizer Investigational Site
    • Halifax
      • Salterhebble, Halifax, Vereinigtes Königreich, HX6 0PW
        • Pfizer Investigational Site
    • Hants
      • Gosport, Hants, Vereinigtes Königreich, PO12 2AA
        • Pfizer Investigational Site
    • Middlesex
      • Northwood, Middlesex, Vereinigtes Königreich, HA6 2RN
        • Pfizer Investigational Site
    • N. Ireland
      • Londonderry, N. Ireland, Vereinigtes Königreich, BT47 1SB
        • Pfizer Investigational Site
    • N. Yorkshire
      • Harrogate, N. Yorkshire, Vereinigtes Königreich, HG2 7SX
        • Pfizer Investigational Site
    • Somerset
      • Taunton, Somerset, Vereinigtes Königreich, TA1 5DA
        • Pfizer Investigational Site
    • South Wales
      • Swansea, South Wales, Vereinigtes Königreich, SA2 8QA
        • Pfizer Investigational Site
    • Yorkshire
      • York, Yorkshire, Vereinigtes Königreich, Y03 7He
        • Pfizer Investigational Site
  • Ägypten
      • Cairo, Ägypten
        • Pfizer Investigational Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

30 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease

Exclusion Criteria:

  • unresectable breast cancer
  • ER negative primary tumor

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: B
Arzneimittel: Tamoxifen
Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
Experimental: EIN
Arzneimittel: Exemestane
Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study
Zeitfenster: Baseline up to Month 36
DFS defined as time from randomization to earliest documentation of breast cancer relapse or death from any cause. DFS at Month 36 post-randomization was defined as probability of participants alive and disease-free at 36 months after the randomization. Participants withdrawn from the study for any reason in the absence of relapse were censored at the date they were last seen. Relapse was categorized as follows: loco-regional: ipsilateral breast or axillary nodal relapse; distant: distant relapse, including supraclavicular nodes; second primary breast cancer: contralateral breast cancer, excluding ductal carcinoma in situ.
Baseline up to Month 36

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall Survival (OS) at Month 36 Post-Randomization: Main Study
Zeitfenster: Baseline up to Month 120
OS was defined as the duration from randomization to death (due to any cause). OS at Month 36 post-randomization was defined as probability of participants' survival at 36 months after the randomization. For participants who were alive, OS was censored at the last available assessment. Probability of OS at Month 36 post-randomization was reported using Kaplan-Meier estimates at Month 36 post-randomization based on 120-month follow-up data.
Baseline up to Month 120
Number of Events of Second Breast Cancer in Contralateral Breast: Main Study
Zeitfenster: Baseline up to Month 120
Number of events of second primary breast cancer in contralateral breast (excluding ductal carcinoma in situ) were reported.
Baseline up to Month 120
Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
Zeitfenster: Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Percent Change From Baseline in Femoral Neck and Femoral Wards Bone Mineral Density (BMD) at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
Zeitfenster: Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
BMD measurements for femoral neck (FN) and femoral wards (FW) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) T-scores at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
Zeitfenster: Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip [TH]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. Results were scored as T-score. T-score indicated how many standard deviations higher or lower participant's value was when compared to the young normal reference mean. Using the World Health Organization (WHO) criteria for osteoporosis, a T-score of greater than or equal to (>=)-1.0 was classified as normal, a T-score of greater than -2.5 to less than -1.0 as osteopenic, and a T-score less than or equal to (<=)-2.5 as osteoporotic. Here 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Percentage of Bone Specific Alkaline Phosphatase (BAP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Bone specific alkaline phosphatase (BAP) serum concentration analyzed using enzyme immuno assay (EIA) at post-baseline time points was expressed as percentage of baseline BAP serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of C-Terminal Telopeptide (CTX) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
C-terminal telopeptide (CTX) serum concentration analyzed using competitive enzyme-linked immunosorbent assay (ELISA) at post-baseline time points was expressed as percentage of baseline CTX serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of Osteocalcin (OC) and Procollagen T1 C-Peptide (PICP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Osteocalcin (OC) serum concentration analyzed using ELISA and procollagen T1 c-peptide (PICP) serum concentration analyzed using sandwich EIA at post-baseline time points was expressed as percentage of baseline OC serum concentration and baseline PICP serum concentration, respectively. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points, for each group respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of Deoxy-pyridinoline (DPD) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Deoxy-pyridinoline (DPD) urine concentration (adjusted for urinary creatinine) analyzed using competitive EIA at post-baseline time points was expressed as percentage of baseline DPD urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Percentage of N-telopeptide of Type 1 Collagen (NTX) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
N-telopeptide of Type 1 collagen (NTX) urine concentration (adjusted for urinary creatinine) analyzed using competitive inhibition EIA at post-baseline time points was expressed as percentage of baseline NTX urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Number of Participants With Fracture: Bone Metabolism Sub-study
Zeitfenster: Baseline up to 24 months post-treatment
Baseline up to 24 months post-treatment
Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The TOI was defined as the sum of 23 items based on following Functional Assessment of Cancer Therapy - Breast version [FACT-B] subscales: Physical well-being (7 items), Functional well-being (7 items), Breast cancer subscale (9 items). Each item was scaled from 0='Not at all' to 4='Very much'. Total TOI score ranged from 0 to 92, where higher TOI score indicated better health-related quality of life (QoL). A change of five points in the TOI scores was considered clinically meaningful. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. Results for 30, 36, 48, 60 months were not reported because data for these time points was only summarized as graphical presentation.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The FACT-ES assessed health-related QoL in participants with breast cancer. ES subscale comprised of 18 items (hot flushes,cold sweats,night sweats, vaginal discharge,vaginal irritation,vaginal bleeding,vaginal dryness,discomfort with intercourse,lost interest in sex,gained weight,light headed/dizzy,vomiting,had diarrhea,headaches,felt bloated,breast tenderness,mood swings, felt irritable).Participants indicated how true a statement was for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total FACT-ES score was calculated as sum of all the 18 items and ranged from 0 to 72, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
FACT-GBE assessed health-related quality of life (QoL) in participants with breast cancer. It consisted of 56 items,summarized to 7 subscales(subscale 1 to 6 constituted total FACT-B and subscale 7 constituted total ES):physical well-being(7 items), social/family well-being(7 items),relationship with doctor (2 items),emotional well-being(6 items),functional well-being(7 items),breast cancer subscale(9 items),endocrine symptoms(18 items). Participants indicated how true a statement had been for them using 5-point scale from 0(not at all) to 4(very much). For items that were negatively framed,scores were reversed for analysis so that higher scores equated to good QoL. Total FACT-GBE score=sum of all 56 items(range 0 to 224, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The PWB subscale assessed physical well-being related QoL in participants with breast cancer. PWB subscale comprised of 7 items (energy lack, nausea, family needs, pain, side effects, felt ill, forced to stay in bed). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total PWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better physical well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The SWB subscale assessed social/family well-being related QoL in participants with breast cancer. SWB subscale comprised of 7 items (distant from friends, emotional support, support from friends, family acceptance, family communication, close to main support, sexual satisfaction). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total SWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better social/family well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The RWD subscale assessed relationship with doctor in participants with breast cancer. RWD subscale comprised of 2 items (confidence in doctors, doctor answered questions). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total RWD score was calculated as the sum of the 2 items and ranged from 0 to 8, where higher score indicated better relationship with doctor. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The EWB subscale assessed emotional well-being related QoL in participants with breast cancer. EWB subscale comprised of 6 items (felt sad, proud of coping, lost hope, felt nervous, worried about dying, worried about condition worsening). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equate to a good QoL. Total EWB score was calculated as the sum of the 6 items and ranged from 0 to 24, where higher score indicated better emotional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The FWB subscale assessed functional well-being related QoL in participants with breast cancer. FWB subscale comprised of 7 items (able to work, work fulfilled, able to enjoy life, acceptance of illness, sleeping well, enjoyed normal fun activities, contented with QoL). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total FWB score was calculated as the sum of the 7 items and ranged from 0 to 28, where higher score indicated better functional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Zeitfenster: Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
The BCS subscale assessed health related QoL in participants with breast cancer. BCS subscale comprised of 9 items (short of breath, self-conscious dress, tender/swollen arms, sexually attractive, bothered by hair loss, worried about familial risk, worried about family stress, bothered by weight change, able to feel like a woman). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total BCS score was calculated as the sum of the 9 items and ranged from 0 to 36, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Number of Participants With Severe Endocrine Symptoms: QoL Sub-study
Zeitfenster: Baseline up to 24 months after randomization
Participants indicated prevalence of an endocrine subscale items using a 5-point scale, where 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). Endocrine items were grouped in five categories vasomotor (hot flushes, cold sweats, night sweats, sleeping difficulties), neuropsychological (lack of energy, nervous feeling, lightheaded/dizzy, headaches, mood swings, feeling irritable), gastrointestinal symptoms (nausea, gained weight, vomiting, diarrhea, bloated feeling), gynecological symptoms (vaginal discharge, vaginal irritation, vaginal bleeding, vaginal dryness, discomfort with intercourse, lost interest in sex, breast tenderness) and other symptoms (pain, feeling ill, side effects). Number of participants who reported severe endocrine symptoms (defined as response categories "quite a bit" and "very much") were presented.
Baseline up to 24 months after randomization
Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study
Zeitfenster: 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Endometrial thickness was assessed using transvaginal ultrasound examination. 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Endometrial Thickness: Endometrial Sub-study
Zeitfenster: Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Endometrial thickness was assessed using transvaginal ultrasound examination. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Uterine and Overall Ovary Volume: Endometrial Sub-study
Zeitfenster: 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Uterine volume (UV) and ovarian volume was estimated using ultrasonography. Uterine volume = (longitudinal diameter * transverse diameter * anteroposterior diameter of uterus)/(2*1000). Ovary volume = [(longitudinal diameter * transverse diameter * anteroposterior diameter of ovary) * 3.14]/(6*1000). Overall ovary volume (OV) is calculated as the sum of the right and left ovary volume. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Number of Participants With Polyps, Fibroids and Ovarian Cysts: Endometrial Sub-study
Zeitfenster: 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Number of participants with presence of polyps (POL) and fibroids (FIB) at post-baseline time points compared to the baseline (BL) status of 'yes', 'no' or 'missing' (that is, participants reporting POL/FIB at post-baseline time points who had yes, no or missing POL/FIB status at baseline, respectively) were presented. Result for number of participants with ovarian cysts was not analyzed at post-baseline time points as very few participants reported ovarian cysts at baseline.
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Percentage of Participants With at Least 1 Gynecological Symptoms: Endometrial Sub-study
Zeitfenster: Baseline up to 24 months post-treatment
Gynecological symptoms included bleeding/spotting, pelvic pain, leucorrhoea and vaginal itching.
Baseline up to 24 months post-treatment
Number of Participants With Histological Findings: Endometrial Sub-study
Zeitfenster: Baseline up to 24 months post-treatment
Baseline up to 24 months post-treatment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Pfizer

Mitarbeiter

International Collaborative Cancer Group

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Februar 1998

Primärer Abschluss (Tatsächlich)

1. Juni 2003

Studienabschluss (Tatsächlich)

1. März 2013

Studienanmeldedaten

Zuerst eingereicht

31. Mai 2002

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

31. Mai 2002

Zuerst gepostet (Schätzen)

3. Juni 2002

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

7. Mai 2014

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. April 2014

Zuletzt verifiziert

1. April 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 96-OEXE-031
  • A5991012

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Neoplasien der Brust

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Slovenia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren